Navigation Links
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol
Date:8/14/2014

s us with a clearly defined development and regulatory pathway for Neutrolin in the United States, and we would like to thank the FDA for its continued guidance throughout this process."

CorMedix will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will be hosting a conference call on August 15 at 9:00 a.m. ET to discuss the Company's second quarter 2014 results. 

In order to participate in the conference call, please call 1-866-866-1333 (U.S.), 1-404-260-1421 (outside the U.S.). All participants who dial in will need to give the operator the access code (5380924), first and last name, company name and caller ID.

Reference:  CorMedix.

About CorMedix Inc.

CorMedix Inc. is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Germany is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.  Please see the company's website at www.cormedix.com for additional information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of
'/>"/>

SOURCE CorMedix Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
5. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
6. KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
7. BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
8. Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference
9. Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
10. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
11. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 A German Diabetes ... L. reuteri probiotic enriches human gut microbiota ... insulin secretion.  The study involved daily administration of Nutraceutix,s ... tablets using the patented BIO- tract ® ... stomach acid on their way to the intestinal tract. ...
(Date:7/28/2015)... , July 28, 2015  SeraCare Life Sciences, ... manufacturers, announced today at the American Association of ... a licensing agreement with the University of California, ... 21 (T21), Trisomy 18 (T18) and Trisomy 13 ... for creating "patient-like" reference materials for Non-Invasive Prenatal ...
(Date:7/28/2015)... -- The Physician-Patient Alliance for Health & Safety (PPAHS) ... Your Hospital Stay ." "Help us ensure ... these patients went home from hospital," said Michael ... to the patient stories presented at the ... Continuous Monitoring of Patients on Opioids (shown above). ...
Breaking Medicine Technology:Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2
... Verathon Inc. is pleased to announce that ... manufacturing facility has made enhancements to GlideScope GVL®, ... to better withstand more rigorous vaporized hydrogen peroxide ... disinfection and sterilization systems in the market prompted ...
... /PRNewswire-Asia/ -- Tongjitang Chinese Medicines Company ("Tongjitang" or the ... has called an extraordinary general meeting of shareholders (the ... on Thursday, March 31, 2011, at the Company,s offices ... 1019 Nanhai Avenue, Nanshan District, Shenzhen, 518067 Guangdong Province, ...
Cached Medicine Technology:Verathon Enhances GlideScope® Video Laryngoscopes to Accommodate Newer Vaporized Hydrogen Peroxide Disinfection and Sterilization Systems 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 3
(Date:7/29/2015)... ... July 29, 2015 , ... For the second year in a ... the list of the 50 fastest growing companies in Jacksonville. This annual list is ... On July 16th, a team of Vast Bridges staffers were on hand to receive ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... CanAm Enterprises, ... by USCIS over the past month! I-829 approvals have been granted to investors in ... Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... A June ... Checked for Skin Cancer ," discussed the importance of having regular skin cancer screenings ... person has excessive exposure to ultraviolet rays. When caught early, skin cancer is rarely ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to be ... Little City took a proactive stance and began planning the Children’s Village consisting of ... valuable support to building the third home. , “We are very pleased to have ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto ... the late 1970s, Dr. Cottrell has been making predictions about the economy, politics, ... documents many of these prognostications. He warns that extreme weather conditions and increased ...
Breaking Medicine News(10 mins):Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
... 24 Eastern Michigan University ... the Michigan departments of Energy, Labor & Economic Growth ... Michigan Nurse Corps (MNC) program, this grant will produce ... month period instead of four to six years of ...
... of conventional and complementary medicine now available in your ... Migraine? Stomach ache? Asthma attack? "Natural Cures," the new ... you need 24/7 as a free app on your ... researcher Jacob Teitelbaum, MD, and his wife, nutritionist Laurie ...
... in research to stem ,crippling, expenses , , TUESDAY, March ... Alzheimer,s Association estimates that Alzheimer,s disease and dementia triple ... people who live in nursing homes or assisted living ... each year, researchers found. The association also estimates that ...
... 24 Solos Endoscopy, Inc. (Pink Sheets: SNDY) is ... purchase order for the MammoView(TM) line of surgical endoscopy ... healthcare networks. Sharp Healthcare has 14,000 employees and ... integrated healthcare network in the State of California, where, ...
... Biosciences announced today that the company plans on ... Administration (FDA) to study the potential impact of ... adjunctive therapy in the treatment of multiple sclerosis.Valomaciclovir ... in vitro against a number of herpes-related viruses, ...
... Improves Document Capture, Streamlines Health Records DocumentationDALLAS, ... a leading developer of healthcare software solutions ... partnership with Imagetek, a national leader in ... to strengthen the capture of paper-based documents ...
Cached Medicine News:Health News:EMU Receives $634,000 Grant From State to Help Stem Nursing Shortage 2Health News:Free iPhone 'Natural Cures' App Launched by Jacob Teitelbaum, MD 2Health News:With Alzheimer's, Health-Care Costs Could Triple 2Health News:Solos Endoscopy, Inc. Receives Purchase Order from Leading San Diego Healthcare Provider 2Health News:Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS) 2Health News:iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice 2Health News:iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice 3Health News:iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice 4
Colour video monitors....
Camera and light source in one compact "Plug-and-Play" device....
... system of choice for customers performing routine ... throughput laboratories in more than 50 countries ... Behring is pleased to announce the placement ... ,The customer centered development process of the ...
... The original ultrasonic ... technology, having an 11-year ... a Large array of ... and femoral applications, cemented ...
Medicine Products: